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Age (years; mean, SD) 69.1 (±8.9) 69.5 (±9.1) 68.9 (±8.8)
Male sex (n, %) 1104 (71) 409 (69) 695 (73)
History of hypertension (n, %) 1106 (72) 421 (72) 685 (72)
Systolic blood pressure at randomisation
(mm Hg; mean, SD)
145 (±21.1) 146.9 (±23) 143.9 (±19.8)
History of diabetes (n, %) 370 (24) 134 (23) 236 (25)
History of hypercholesterolaemia (n, %)* 592 (61) 275 (60) 317 (63)
History of smoking (n, %) 988 (64) 372 (63) 616 (65)
History or coronary heart disease (n, %) 358 (23) 146 (25) 212 (22)
History of peripheral artery disease (n, %)* 158 (16) 74 (16) 84 (17)
Stenosis on the left side (n, %) 815 (53) 325 (55) 490 (51)
Ipsilateral degree of stenosis
Moderate (50-69%) (n, %) 305 (20) 96 (16) 209 (22)
Severe (70-99%) (n, %) 1243 (80) 497 (84) 746 (78)
Contralateral severe carotid stenosis or occlusion (n, %) 213 (15) 94 (17) 119 (14)
Qualifying event
Amaurosis fugax or retinal stroke (n, %) 280 (18) 120 (20) 160 (17)
Transient ischemic attack (n, %) 535 (35) 203 (34) 332 (35)
Hemispheric stroke (n, %) 725 (47) 266 (45) 459 (48)
History of stroke prior to qualifying event (n, %)* 162 (17) 92 (20) 70 (14)
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Legend: Patients with deployed stents and available data on stent type are included. Data are
n/N (%), unless otherwise indicated. *Data were not gathered in the Stent-Protected
Angioplasty versus Carotid Endarterectomy (SPACE) trial. †Modified Rankin scores at
baseline might indicate non-stroke impairments; protocols of contributing trials excluded
patients with disabling strokes.









Stent design (n, %)
Open-cell 595 (38.2) 101 (41.1) 127 (22.2) 367 (49.7)
Precise RX (Cordis) 263 (16.9) 26 (10.6) 35 (6.1) 202 (27.4)
Acculink (Guidant/Abbott) 232 (14.9) 70 (28.5) 92 (16.1) 70 (9.5)
Protégé (EV3) 82 (5.3) 0 (0.0) 0 (0.0) 82 (11.1)
Next Stent (Boston Scientific) 3 (0.2) 0 (0.0) 0 (0.0) 3 (0.4)
Exponent (Medtronic) 3 (0.2) 0 (0.0) 0 (0.0) 3 (0.4)
Zilver (Cook Medical) 5 (0.3) 5 (2.0) 0 (0.0) 0 (0.0)
S.M.A.R.T. (Cordis) 7 (0.4) 0 (0.0) 0 (0.0) 7 (0.9)
Closed-cell 962 (61.8) 145 (58.9) 446 (77.8) 371 (50.3)
Carotid Wallstent (Boston
Scientific)
899 (57.7) 145 (58.9) 436 (76.1) 318 (43.1)
Xact (Abbott) 58 (3.7) 0 (0.0) 10 (1.7) 48 (6.5)
Cristallo ideale
(Invatec/Medtronic)
5 (0.3) 0 (0.0) 0 (0.0) 5 (0.7)
Protection device used (n, %) 950 (61.0) 227 (92.3) 153 (26.7) 570 (77.2)
Distal filters* 827 (87.1) 160 (70.5) 133 (86.9) 534 (93.7)
Accunet (Guidant) 15 (1.6) 5 (2.2) 4 (2.6) 6 (1.1)
Angioguard (Cordis) 124 (13.1) 21 (9.3) 16 (10.5) 87 (15.3)
Emboshield (Abbott) 131 (13.8) 24 (10.6) 18 (11.8) 89 (15.6)
Filterwire (Boston Scientific) 374 (39.4) 61 (26.9) 66 (43.1) 247 (43.3)
Interceptor (Medtronic) 1 (0.1) 0 (0.0) 0 (0.0) 1 (0.2)
Mednova Neuroshield (Abbott) 29 (3.1) 0 (0.0) 5 (3.3) 24 (4.2)
Spider (EV3) 153 (16.1) 49 (21.6) 24 (15.7) 80 (14.0)
Distal occlusion* 86 (9.1) 67 (29.5) 16 (10.5) 3 (0.5)
Percusurge (Medtronic) 86 (9.1) 67 (29.5) 16 (10.5) 3 (0.5)
Flow reversal* 34 (3.6) 0 (0.0) 4 (2.6) 30 (5.3)
Neuroprotection System (GORE) 22 (2.3) 0 (0.0) 0 (0.0) 22 (3.9)
Mo.Ma (Invatec) 5 (0.5) 0 (0.0) 4 (2.6) 1 (0.2)
Parodi AES (Arteria) 7 (0.7) 0 (0.0) 0 (0.0) 7 (1.2)
Type of device unknown* 0 0 0 3 (0.5)
Pre-dilatation performed (n, %)† 760 (48.8) 41 (16.7) 194 (33.9) 525 (71.1)
Post-dilatation performed (n, %)† 1177 (89.8) 0 (0.0) 552 (96.3) 625 (84.7)
Double APT used (n, %)† 1357 (88.8) 191 (77.6) 546 (95.3) 620 (87.0)
Legend: Patients with deployed stents and available data on stent type and protection device
use are included. Data are n/N (%), unless otherwise indicated.*Percentages of all protection
devices. †Percentages exclude missing data; missing data were: pre-dilatation (n=1 patient),
post-dilatation (n=246), antiplatelet therapy (n=29).
4Supplementary table 3: Risk of procedural stroke or death in the stenting versus
endarterectomy groups at study centers according to the frequency of closed-cell stent
use
Frequency of closed-cell
stent use at center





Events / patients Events / patients
>80% closed-cell stents 42/677 (6.2%) 33/700 (4.7%) 1.31 (0.84, 2.03)
20-80% closed-cell stents 54/615 (8.8%) 29/640 (4.5%) 1.93 (1.25, 3.00) P=0.062
<20% closed-cell stents 19/231 (8.2%) 6/238 (2.5%) 3.24 (1.32, 7.96)
Legend: Crude risks (number of events divided by number of patients) and binomial
regression estimates of risk ratios (RR) and 95% confidence intervals (CI) of any stroke or
death within 30 days of treatment are provided for patients treated with stenting compared
with patients treated with endarterectomy. Centers were excluded if they had <4 CAS
procedures with known stent design. CAS, carotid artery stenting; CEA, carotid
endarterectomy.
5Supplementary figure 1: Effect of stent treatment with versus without use of protection
devices in contributing trials.
Percentages are number of events divided by number of patients. Squares and horizontal bars
represent within-trial treatment risk ratios and 95% CIs, respectively, with unprotected
stenting as the reference group, on a log scale. The size of squares represents study weight.
The diamond represents the pooled risk ratio and 95% CI, adjusted for source trial. In the
investigation of heterogeneity, the interaction p value represents the significance of the
interaction between source trial and treatment effect in the regression model (likelihood ratio
test); a significant p value suggests heterogeneity. EVA-3S=Endarterectomy versus
Angioplasty in Patients with Symptomatic Severe Carotid Stenosis. SPACE=Stent-Protected
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6Supplementary figure 2: Effect of stent treatment with versus without use of protection
devices on risk of procedural stroke or death according to stent design and patient age.
Percentages are number of events divided by number of patients. Squares and horizontal bars
represent treatment risk ratios and 95% CIs within subgroups, respectively, with unprotected
stenting as the reference group, on a log scale, adjusted for source trial. The diamond
represents the overall risk ratio and 95% CI for protected versus unprotected stenting,
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Since NASCET1 had proven carotid revascularisation by means of endarterectomy (CEA) to
significantly reduce the risk of stroke in symptomatic carotid disease, CEA has become the
gold standard of treatment. Besides a risk of peri-procedural stroke however, CEA carries
some risk of general complications related to surgery and anaesthesia, as well as morbidity
related to incision in the neck such as cranial nerve palsy and haematoma. In recent years,
endovascular treatment with placement of a stent has been advocated as a less invasive
alternative to endarterectomy. Carotid artery stenting (CAS) has potential advantages over
endarterectomy: general and local surgical complications could be avoided and hospital stay
may be shortened. However, stenting may also cause stroke during the intervention, either due
to thrombo-embolism or release of atheromatous emboli. The development of thrombotic
material on the disrupted vessel wall or at the foreign body, the stent, had drastically been
reduced by combined platelet aggregation inhibition (aspirin and clopidogrel).2,3In contrast,
there is ongoing uncertainty whether the use of cerebral protection devices reduces the risk of
embolism of atheromatous or thrombotic material during CAS. The advocates of protection
declare, that filters like bow nets in the distal ICA would be necessary, in order to protect the
brain by means of removing emboli from the circulation. The advocates of unprotected
stenting plead against the additional manipulation of endovascular material as it might
increase the risk of dislodging emboli or injuring the vessel wall with subsequent thrombus
formation or dissection. Furthermore the observation was made, that seemingly different
stents - possibly depending on the stent design - are associated with a different frequency of
complications. This supported the hypothesis that the tight, “closed” stent design caused less
often adverse outcome events than wide mash “open” stent design.4
In three large randomised clinical trials of symptomatic carotid disease which contribute to
the Carotid Stenting Trialists Collaboration (CSTC), stenting has been performed with and
without protection. In the French Endarterectomy versus Angioplasty in Patients with
Symptomatic Severe Carotid Stenosis trial (EVA-3S)5, the use of protection devices became
mandatory after unfavourable initial results in 33 patients treated without protection; 227
patients were treated with protection devices. In the German, Swiss, and Austrian Stent-
Protected Angioplasty versus Carotid Endarterectomy in symptomatic patients trial
(SPACE)6, 154 patients were treated with, and 424 were treated without protection devices,
among those receiving stenting as randomly allocated (per-protocol). The International
Carotid Stenting Study (ICSS)7, reported on 593 protected and 208 unprotected per-protocol
CAS procedures. The unprotected cohort in EVA 3S5 was too small for a comparative
analysis of the data. However the analysis for ICSS data demonstrated a short-term rate for
ipsilateral stroke and death with protection versus non-protection of 6.1% versus 4.6%, and
for SPACE the results were 8.3% versus 6.2%.
In the North American Carotid Revascularization Endarterectomy versus Stenting Trial
(CREST)8, which recruited both patients with symptomatic and patients with asymptomatic
carotid stenosis, use of protection devices was mandatory from the beginning. The rate any
stroke or death up to 30 days after treatment in the stenting arm was 4.4%. Among patients
with symptomatic carotid disease however the peri-procedural stroke-or-death rate in CREST
was 6.0%, which was similar to the combined results of the European trials. The currently
available evidence therefore does not warrant the necessity of protection devices for CAS
procedures.
8The observation that the design of the stent might influence the OE rate has been observed by
Bosiers and Cremonesi in 2006 already, who found in symptomatic carotid disease a rate of
2.2% for closed and 7.0% for open cell design.4 Jansen et al. analysed the data for SPACE
patients and found an OE rate for closed cell stent: (5.6%, 95% CI: 3.7 to 8.2%]) and open
cell stent (11.0%, 95% CI: 6.2 to 17.8%).9 The hypothesis generated on the basis of these
findings was that the tight close cell design might cover the plaque better than the wide mesh
of open cell stents and hence restrain more debris from escaping into the blood stream.
It may not only be the actual placement of the stent onto the stenosis, which causes
mechanical impact on intact intima and the atheromatous plaque. Single or multiple balloon
dilatations of the stenosis before or after stent insertion (so-called pre- and postdilatation)
have been suspected to be a potential cause of embolic events, which might be even more
important in combination with open or closed cell design.10
The influence of clinical and demographic patient characteristics on the risk of peri-
procedural stroke in stenting has been an important focus of research: most consistently,
increasing age has been associated with increasing stroke risk.11 The initial pooled analysis of
the European trials in the CSTC showed that the risks of stroke or death in the short-term
were similar between CAS and CEA in patients younger than 70 years, whereas the
comparison strongly favoured CEA in the older patient group. As this was a completely
unexpected finding at the time these trials were designed, age-related anatomical and
physiological data have not been prospectively defined and systematically collected in the
trials. Therefore, the exact mechanism mediating the interaction between age and the relative
risk of complications with stenting versus endarterectomy remains to be determined; it is
conceivable that an increase in the general burden of atherosclerosis (including the aortic
arch) or changes in the vascular anatomy of supra-aortic arteries or in the composition of
atherosclerotic plaques render elderly patients more susceptible to thromboembolic
complications during CAS. Other clinical variables, such as type of the most recent ischaemic
event before randomisation and delay between the event and treatment might be associated
with plaque instability. Any of these factors might therefore influence the impact of stent cell
design, use or protection devices or pre- or postdilatation on procedural risks, and should
therefore be analysed in conjunction with the technical variables.
Due to limitations in sample size, such analyses could not be performed with sufficient
statistical power at the level of individual trials.
Objective
To overcome the limitations of single trials, the investigators of the European-led stenting
trials (EVA-3S, SPACE, and ICSS)5–7have set up the Carotid Stenting Trialists’ Collaboration
(CSTC) with the purpose of conducting a combined analysis of outcome data from individual
patients randomised for CAS in these trials. The objectives of the present analysis are to
investigate the effect of the use of protection devices and the cell design of stents, as well as
other procedure-related, clinical or demographic variables on the peri-procedural risk of
stroke or death associated with stent treatment for symptomatic carotid stenosis. The
following protocol for this analysis has been agreed by the CSTC Steering Committee before
the data from the contributing trials were pooled and analysed.
9Methods
Contributing trials
The individual patient data meta-analysis of EVA-3S (NCT 00190398), SPACE (ISRCTN
57874028), and ICSS (ISRCTN 25337470) was prospectively agreed at the design stage of
the trials. Patient eligibility criteria, interventions, collected baseline characteristics, and
definitions of outcome events were therefore broadly similar between the contributing trials.
All three were open clinical trials with blinded outcome adjudication, randomising patients
with moderate or severe carotid stenosis (≥50% reduction of the lumen diameter, measured 
according to the method used in NASCET) and associated recent, non-disabling ocular or
cerebral ischaemic events, who were equally suited for either procedure, to undergo treatment
by stenting or endarterectomy. The use of approved cerebral protection devices was optional
in SPACE and ICSS. In contrast protection devices were made mandatory in EVA-3S after an
interim analysis revealed a higher risk of procedural stroke with unprotected stenting
compared with protected stenting (see above).
Definition of outcome events
The primary outcome event of the present analysis is any stroke or death occurring between
the day of procedure and 30 days thereafter. The exact time of the onset of outcome events in
relation to the procedure was not systematically collected in the contributing trials; for the
present analysis, we therefore assumed that outcome events occurring on the day the
procedure took place occurred as an immediate complication thereof. In order to investigate
whether associations between technical variables and the 30-day risk of stroke or death were
driven by immediate complications of the procedure, we performed a sensitivity analysis
including only stroke and death outcomes occurring on the day of procedure. Outcome events
are defined in the protocol for the CSTC pooled analysis of short-term outcome events, which
was published in the supplementary web-appendix to the original CSTC paper.12
Per protocol definition
The analysis will be done per-protocol, including only patients who were randomised to
stenting and in whom a stent was deployed across the stenosis. Patients who did not receive
stent treatment as randomly allocated will be excluded (i.e., those randomised to stenting in
whom the procedure was abandoned before a stent was inserted; those randomised to stenting
and crossing over to surgery, those randomised to surgery and crossing over to stenting; those
remaining on medical treatment without any attempt at revascularisation; and those who died
before treatment).
Selection of variables
The association between peri-procedural outcome events and the following primary
procedure-related variables of interest will be assessed: use of protection device and type of
stent cell design (open-cell versus closed-cell). We defined closed-cell designs for stents that
show a small open area (< 5•0 mm2) between the cell struts and therefore a higher coverage
rate and where all stent-struts are interconnected; open cell designs for stents showing a
greater open area (> 5•0 mm2) and without interconnection between all stent struts (Table
II).4 We included all types of protection devices and defined five different categories (distal
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filter, distal balloon, proximal balloon, flow reversal, others) (Table III). Other procedure-
related variables include predilatation, postdilatation and type of peri-procedural
antithrombotic treatment (Table I). In addition, the association between peri-procedural
outcome events and the following clinical and demographic variables will be assessed: exact
age at the time of treatment (calculated as the difference between date of birth and date of
treatment), sex, history of diabetes, hypertension, hypercholesterolaemia, smoking (current or
past), coronary heart disease, and peripheral artery disease; type of the most recent ischaemic
event (retinal ischaemia including transient monocular blindness or retinal infarct,
hemispheric transient ischaemic attack, or hemispheric ischaemic stroke) in the region
supplied by the ipsilateral carotid artery before randomisation; history of stroke before the
most recent ipsilateral ischaemic event; systolic blood pressure at randomisation; level of
functional disability at randomisation measured by the modified Rankin Score; degree of
ipsilateral carotid stenosis determined at randomisation according to NASCET1 criteria or
non-invasive equivalent (moderate [50-69% luminal diameter reduction], or severe [70-99%])
and side of the stenosis (left/right); and presence of contralateral severe carotid stenosis or
occlusion. All collected patient and procedure related characteristics will serve as variables in
analysis. Table I lists all pre-defined variables
Statistical analysis
As the protocols of the three contributing trials are broadly similar, statistical heterogeneity
between the treatment effects in individual trials is expected to be small. Individual patient
data will therefore be pooled and primarily analysed with fixed-effect binomial regression
models including source trial terms as covariables, in order to obtain an overall unadjusted
estimate of risk ratios (RR) and 95% confidence intervals of major outcome events as primary
aggregate measures of treatment effect. Nevertheless, potential heterogeneity of the individual
trial treatment effects will be examined by testing for interactions between source trial and
treatment effect in the binomial regression model. If substantial heterogeneity is found,
secondary random effects analyses will also be performed.
Associations between the pre-defined variables and peri-procedural outcome events will first
be assessed on a univariable level (unadjusted risk ratios). Secondly, RR will be adjusted for
(A) only those factors that change the crude RR by more than 5% on a relative scale; (B)
simultaneously for the three factors that have the most influence on the RR, as well as (C) for
all factors that change the RR. Differences between the effects of protection devices on the
primary outcome measure in (1) older versus younger patients and (2) in open-cell versus
closed-cell stenting will be investigated by formal testing of statistical interaction. The former
interaction will be adjusted for stent design; the latter will be adjusted for age.
Discussion
The prospective meta-analysis of individual patient data from three large randomised trials in
the Carotid Stenting Trialists’ Collaboration represents a powerful tool to analyse the impact
of procedural variables on the safety of stent treatment for symptomatic carotid stenosis. The
pooled analysis has the potential to identify particular patient groups in whom stenting in
general or specific techniques of stenting are associated with increased procedural risks.
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Stent design (open cell vs. closed cell design)
Stent model
Single versus double peri-procedural antiplatelet therapy
Use of protection device
Duration of CAS
Clinical and demographic variables Age at treatment
Coronary heart disease




Presence of contralateral stenosis or occlusion
Sex
Side of stenosis (left/right)
Smoking (current or past)
Type of the most recent ipsilateral ischaemic event before randomisation
Table II: Types and categorisation of stents used in EVA-3S, SPACE and ICSS
Closed-cell design Carotid Wallstent (Boston Scientific)
Xact (Abbott)
Cristallo ideale (Invatec)
Open-cell design Precise RX (Cordis)
Acculink (Guidant/Abbott)
Protégé (EV3)
Next Stent (Boston Scientific)
Exponent (Medtronic)
Table III: Types of Protection-Devices used in EVA-3s, SPACE and ICSS
Distal Filter Spider (EV3)





Distal balloon GuardWire Plus (Medtronic)
Proximal balloon MO.MA (Invatec)
Flow reversal PercuSurge (Medtronic)
Gore Neuroprotection System (Gore)
Other Parodi anti embolism system (Arteria Medical Science)
